Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cholera - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Cholera - Pipeline Review, H2 2016', provides an overview of the Cholera pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cholera and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Cholera - The report reviews pipeline therapeutics for Cholera by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Cholera therapeutics and enlists all their major and minor projects - The report assesses Cholera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Cholera Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cholera - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cholera Overview 6 Therapeutics Development 7 Pipeline Products for Cholera - Overview 7 Pipeline Products for Cholera - Comparative Analysis 8 Cholera - Therapeutics under Development by Companies 9 Cholera - Therapeutics under Investigation by Universities/Institutes 10 Cholera - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Cholera - Products under Development by Companies 14 Cholera - Products under Investigation by Universities/Institutes 15 Cholera - Companies Involved in Therapeutics Development 16 Beijing Minhai Biotechnology Co., Ltd 16 MSD Wellcome Trust Hilleman Laboratories, Pvt. Ltd. 17 Cholera - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 cholera (trivalent) vaccine - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 cholera [strain O1/El/Tor/Ogawa] vaccine - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 cholera vaccine - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Cholvax - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 crofelemer DR - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 gram-negative bacterial infections vaccine - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 IMSUTMR-1501 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecules for Bacterial Infections - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Synthetic Peptides to Disrupt Cell Membrane for Bacterial and Fungal Infections - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Cholera - Dormant Projects 40 Cholera - Discontinued Products 41 Cholera - Product Development Milestones 42 Featured News & Press Releases 42 Apr 27, 2016: Hilleman Laboratories Provides Phase I/II Update on Cholera Vaccine 42 Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix 42 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Number of Products under Development for Cholera, H2 2016 7 Number of Products under Development for Cholera - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Cholera - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 16 Cholera - Pipeline by MSD Wellcome Trust Hilleman Laboratories, Pvt. Ltd., H2 2016 17 Assessment by Monotherapy Products, H2 2016 18 Number of Products by Stage and Target, H2 2016 20 Number of Products by Stage and Mechanism of Action, H2 2016 22 Number of Products by Stage and Route of Administration, H2 2016 24 Number of Products by Stage and Molecule Type, H2 2016 26 Cholera - Dormant Projects, H2 2016 40 Cholera - Discontinued Products, H2 2016 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
